Olympus Corporation announced the appointments of Dr. Thomas Gildea and Dr. Tamás Ötvös to the Medical & Scientific Affairs organization to help drive innovation and patient safety for the respiratory business
Olympus Corporation has appointed Dr. Thomas R. Gildea as Global Lead for Medical Affairs in its Respiratory division and Dr. Tamás Ötvös as Global Clinical Lead and Director of Clinical Research. This announcement, made on November 11, 2025, aims to drive innovation and improve patient safety in the respiratory healthcare sector.
The appointments reflect Olympus’ commitment to enhancing its Medical & Scientific Affairs (MSA) team, focusing on developing advanced medical technologies. Dr. Gildea’s extensive background in interventional pulmonology and medical device development positions him to guide Olympus’ medical strategy effectively. Meanwhile, Dr. Ötvös brings significant expertise in clinical trials and translational science, tasked with spearheading impactful studies that promote minimally invasive respiratory care.
Strengthening Leadership in Respiratory Medicine
Dr. Gildea joins Olympus after a distinguished 22-year career at the Cleveland Clinic. He has held various roles, including Section Head of Bronchoscopy and Interventional Pulmonology. His leadership contributed to the expansion of the bronchoscopy program, increasing procedural volumes from around 1,500 cases annually to over 5,000.
“I am excited to serve a broader patient population through a global MedTech company,” said Dr. Gildea. He aims to bridge the gap between clinical practice and medical technology, fostering innovations that improve the detection and treatment of respiratory diseases. His prior achievements include receiving a National Institutes of Health Accelerated Innovation Award for developing custom airway stents, which led to FDA approval and the establishment of a spin-off company, VisionAir.
Dr. Gildea has also been active in advocating for improved patient access to bronchoscopy services, working with the American Thoracic Society to enhance coding for procedures like endobronchial ultrasound.
Dr. Ötvös, a renowned pulmonary physician-scientist, completed a postdoctoral fellowship at the Johns Hopkins University School of Medicine. His research has spanned pulmonary physiology, airway mechanics, and sleep disorders, aiming to advance the understanding of respiratory conditions. At Olympus, he will lead the global clinical evidence strategy for various respiratory devices, including bronchoscopic lung volume reduction and endobronchial valve therapy.
Commitment to Patient-Centered Innovation
Both new leaders will play pivotal roles in ensuring Olympus’ respiratory devices meet the highest standards of safety and efficacy. Dr. Ötvös emphasized the company’s potential impact, stating, “As a global MedTech company, Olympus has an opportunity to positively impact countless patients by helping physicians detect, diagnose, and treat respiratory diseases.”
The appointments of Dr. Gildea and Dr. Ötvös underscore Olympus’ dedication to patient-focused innovation. The MSA team is committed to collaborating with healthcare professionals to identify unmet needs in respiratory care and deliver effective medical solutions. This partnership is crucial for expanding equitable healthcare access and improving patient outcomes worldwide.
Olympus Corporation, headquartered in Center Valley, Pennsylvania, employs over 4,500 individuals across North and South America. As a global medical technology leader, Olympus is focused on improving healthcare through innovative solutions and services for early detection, diagnosis, and minimally invasive treatment. For more information about their initiatives, visit olympusamerica.com.
